血糖全面达标的降糖治疗策略之再探讨

Re-discussion of Antihyperglycemic Treatment Strategy for Blood Glucose Management

降糖理念几经变迁,控制血糖仍是众多理念中的核心问题。糖化血红蛋白(HbA1c)是评估长期降糖疗效的“金标准”,而空腹血糖(FPG)和餐后血糖(PPG)是整体血糖的重要组成部分,能反映短期血糖波动,并可作为调整治疗方案的指导。因此,降糖治疗策略制定时,不仅要关注HbA1c,FPG和PPG也是衡量血糖全面达标的重要指标。本文将结合临床研究探讨适合我国2型糖尿病(T2DM)患者血糖全面达标的降糖治疗方案。

Hemoglobin A1c(HbA1c)is the"gold standard"for evaluating long-term antihyperglycemic efficacy,while Fasting Plasma Glucose(FPG)and Postprandial Plasma Glucose(PPG)are important components of overall blood glucose,which can reflect short-term blood glucose fluctuations and can be used as guidance to adjust treatment regimens.Therefore,when an antihyperglycemic treatment strategy is made,we should not only pay attention to HbA1c,FPG and PPG are also important indicators of overall blood glucose control.This paper will discuss antihyperglycemic treatment regimens suitable for type 2 diabetes mellitus(T2DM)patients in China in the context of clinical trials.